Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors.

Farrell PJ, Zopf CJ, Huang HJ, Balakrishna D, Holub C, Bilakovics J, Fanjul A, Matuszkiewicz J, Plonowski A, Rolzin P, Banerjee U, Ermolieff J, Cheruvallath ZS, McBride C, Bartkowski D, Mazur C, Pachori A, Larson CJ.

J Pharmacol Exp Ther. 2019 Nov;371(2):299-308. doi: 10.1124/jpet.119.259028. Epub 2019 Sep 19.

PMID:
31537613
2.

First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.

Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS.

Int J Cancer. 2019 Oct 1;145(7):1798-1808. doi: 10.1002/ijc.32154. Epub 2019 Feb 23.

PMID:
30680712
3.

A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.

King GT, Eaton KD, Beagle BR, Zopf CJ, Wong GY, Krupka HI, Hua SY, Messersmith WA, El-Khoueiry AB.

Invest New Drugs. 2018 Oct;36(5):836-847. doi: 10.1007/s10637-018-0560-6. Epub 2018 Jan 15.

PMID:
29333575
4.

Cell-cycle dependence of transcription dominates noise in gene expression.

Zopf CJ, Quinn K, Zeidman J, Maheshri N.

PLoS Comput Biol. 2013;9(7):e1003161. doi: 10.1371/journal.pcbi.1003161. Epub 2013 Jul 25.

5.

Supplemental Content

Support Center